UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (687) 687
science & technology (579) 579
life sciences & biomedicine (553) 553
female (405) 405
male (377) 377
aminopyridines - adverse effects (354) 354
aminopyridines - therapeutic use (350) 350
middle aged (263) 263
adult (244) 244
aminopyridines - pharmacology (240) 240
aminopyridines - administration & dosage (239) 239
animals (222) 222
aged (190) 190
pharmacology & pharmacy (179) 179
benzamides - therapeutic use (135) 135
biological and medical sciences (129) 129
medical sciences (128) 128
treatment outcome (121) 121
pulmonary disease, chronic obstructive - drug therapy (118) 118
oncology (116) 116
cyclopropanes - therapeutic use (113) 113
roflumilast (112) 112
aminopyridines - pharmacokinetics (108) 108
benzamides - adverse effects (108) 108
respiratory system (105) 105
abridged index medicus (102) 102
double-blind method (96) 96
cyclopropanes - adverse effects (94) 94
mice (90) 90
benzamides - pharmacology (87) 87
dose-response relationship, drug (87) 87
drug therapy (86) 86
pharmacology. drug treatments (82) 82
research (80) 80
administration, oral (79) 79
care and treatment (79) 79
cyclopropanes - pharmacology (75) 75
general & internal medicine (74) 74
benzamides - administration & dosage (72) 72
phosphodiesterase 4 inhibitors - therapeutic use (71) 71
breast neoplasms - drug therapy (68) 68
aminopyridines (66) 66
chronic obstructive pulmonary disease (65) 65
adolescent (64) 64
young adult (64) 64
analysis (63) 63
cyclopropanes - administration & dosage (63) 63
dosage and administration (63) 63
patients (63) 63
breast cancer (62) 62
clinical trials (59) 59
mutation (59) 59
phosphodiesterase 4 inhibitors - adverse effects (58) 58
rats (57) 57
amrinone (56) 56
disease models, animal (55) 55
medicine & public health (55) 55
drug therapy, combination (54) 54
clinical trials as topic (53) 53
medicine, general & internal (51) 51
neurosciences & neurology (51) 51
breast neoplasms - pathology (48) 48
heart failure - drug therapy (48) 48
tumors (48) 48
drug interactions (47) 47
aged, 80 and over (46) 46
analgesics - adverse effects (46) 46
cyclin-dependent kinase 4 - antagonists & inhibitors (46) 46
phosphodiesterase 4 inhibitors - pharmacology (46) 46
benzamides - pharmacokinetics (45) 45
cancer (45) 45
time factors (45) 45
lung diseases, obstructive (44) 44
phosphodiesterase inhibitors - therapeutic use (44) 44
cyclin-dependent kinase 6 - antagonists & inhibitors (43) 43
pharmacokinetics (43) 43
kinases (42) 42
pulmonary disease, chronic obstructive - physiopathology (42) 42
cystic fibrosis - drug therapy (41) 41
disease progression (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
cystic fibrosis (40) 40
pharmacology (40) 40
cyclopropanes - pharmacokinetics (39) 39
neurosciences (38) 38
studies (38) 38
antineoplastic agents - adverse effects (37) 37
bronchodilator agents - therapeutic use (37) 37
internal medicine (37) 37
pharmacology/toxicology (37) 37
phosphodiesterase 4 inhibitors - administration & dosage (37) 37
cystic fibrosis transmembrane conductance regulator - genetics (36) 36
proteins (36) 36
cardiotonic agents - therapeutic use (35) 35
phosphodiesterase 4 inhibitors (35) 35
pulmonary/respiratory (35) 35
quinolones - therapeutic use (35) 35
4-aminopyridine (34) 34
asthma (34) 34
copd (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (786) 786
German (29) 29
Spanish (5) 5
French (4) 4
Japanese (4) 4
Russian (2) 2
Italian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9971, pp. 857 - 866
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 11/2017, Volume 85, pp. 133 - 145
Buparlisib | Neoadjuvant | NeoPHOEBE | HER2 | Primary breast cancer | pCR | Life Sciences & Biomedicine | Oncology | Science & Technology | Class I Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Protein Kinase Inhibitors - adverse effects | Early Termination of Clinical Trials | Breast Neoplasms - enzymology | Time Factors | Biomarkers, Tumor - metabolism | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Chemical and Drug Induced Liver Injury - etiology | Morpholines - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Europe | Morpholines - administration & dosage | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Lymphocytes, Tumor-Infiltrating - drug effects | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Aged | Biomarkers, Tumor - genetics | Mutation | Australia | Antimitotic agents | Clinical trials | Product development | Breast cancer | Antineoplastic agents | Therapy | Toxicity | Liver | Taxane | Patients | ErbB-2 protein | Subgroups | 1-Phosphatidylinositol 3-kinase | Randomization | Epidermal growth factor | Inhibitors | Lymphocytes | Paclitaxel | Growth factors | Trastuzumab | Cancer | Tumors | Index Medicus
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 2016, Volume 138, Issue 1, pp. 142 - 149.e8
Allergy and Immunology | phosphodiesterase 4 inhibitors | roflumilast | montelukast | Asthma | Allergy | Immunology | Life Sciences & Biomedicine | Science & Technology | Anti-Asthmatic Agents - adverse effects | Spirometry | Acetates - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Cyclopropanes - adverse effects | Quinolines - administration & dosage | Cyclopropanes - therapeutic use | Forced Expiratory Volume | Benzamides - administration & dosage | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Cyclopropanes - administration & dosage | Leukotriene Antagonists - administration & dosage | Aged, 80 and over | Female | Acetates - therapeutic use | Leukocyte Count | Drug Therapy, Combination | Benzamides - adverse effects | Leukotriene Antagonists - adverse effects | Leukotriene Antagonists - therapeutic use | Asthma - diagnosis | Severity of Illness Index | Aminopyridines - administration & dosage | Risk Factors | Treatment Outcome | Asthma - drug therapy | Disease Progression | Acetates - administration & dosage | Aged | Quinolines - therapeutic use | Anti-Asthmatic Agents - administration & dosage | Quinolines - adverse effects | Care and treatment | Research institutes | Analysis | Medical research | Medicine, Experimental | Respiratory agents | Roflumilast | Genotype & phenotype | Neutrophils | Chronic obstructive pulmonary disease | Infections | Bronchitis | Patients | Methods | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 220 - 231
Journal Article